I. Macdougall

发表

Anemia with erythropoietin deficiency occurs early in diabetic nephropathy.

A. Winkler, D. Bosman, J. Marsden, 2001, Diabetes care.

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.

I. Macdougall, F. Locatelli, R. Vanholder, 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Examining the efficacy of social-psychological interventions for the management of fatigue in end-stage kidney disease (ESKD): a systematic review with meta-analysis

I. Macdougall, R. Moss‐Morris, J. Chilcot, 2017, Health psychology review.

Long-Term Cardiorespiratory Effects of Amelioration of Renal Anaemia by Erythropoietin

I. Macdougall, D. Cochlin, N. Lewis, 1990 .

Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin

I. Macdougall, D. Cochlin, N. Lewis, 1990, The Lancet.

Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients

I. Macdougall, B. Canaud, S. Stuard, 2016, PloS one.

Clinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin)

I. Macdougall, G. Coles, J. Williams, 1991, Clinical pharmacokinetics.

Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations.

I. Macdougall, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Use of recombinant erythropoietins in the setting of renal disease

I. Macdougall, 2003 .

Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

H. Burger, I. Macdougall, F. Locatelli, 2006, The New England journal of medicine.

Pharmacology of darbepoetin alfa.

I. Macdougall, D. Padhi, G. Jang, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Erythropoietins: a common mechanism of action.

I. Macdougall, S. Elliott, Elizabeth Pham, 2008, Experimental hematology.

Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality.

O. Djurdjev, A. Levin, I. Macdougall, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Hemoglobin variability does not predict mortality in European hemodialysis patients.

F. Kronenberg, S. Anker, I. Macdougall, 2010, Journal of the American Society of Nephrology : JASN.

Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data

Simon de Lusignan, Terry Desombre, S. de Lusignan, 2013, BMC Nephrology.

Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.

I. Macdougall, S. Fishbane, P. Pergola, 2013, The New England journal of medicine.

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial

I. Macdougall, G. Chertow, K. Bernard, 2018, American journal of hematology.

Strategies for iron supplementation: oral versus intravenous.

I. Macdougall, Iain C. Macdougall, I. C. Macdougall, 1999, Kidney international. Supplement.

Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial

Keith C. Norris, K. Kalantar-Zadeh, M. Unruh, 2013, Journal of cachexia, sarcopenia and muscle.

Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial

Keith C. Norris, K. Kalantar-Zadeh, M. Unruh, 2013, Journal of cachexia, sarcopenia and muscle.

Title Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients ( AIONID ) study : Results of the pilot-feasibility , double-blind , randomized , placebo-controlled trial Permalink

Keith C. Norris, K. Kalantar-Zadeh, M. Unruh, 2013 .

Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytoma.

S. Ball, I. Macdougall, K. Lees, 1988, The American journal of medicine.

Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

D. Swinkels, C. Wanner, I. Macdougall, 2019, Kidney international.

Pure red cell aplasia - still the spectre at the feast

I. Macdougall, F. Carrera, 2007 .

Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?

I. Macdougall, F. Locatelli, A. Więcek, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin.

I. Macdougall, J. Małyszko, P. Przybyłowski, 2013, Transplantation proceedings.

Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA.

D. Swinkels, I. Macdougall, J. Wetzels, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Quantitation of hepcidin in serum using ultra-high-pressure liquid chromatography and a linear ion trap mass spectrometer.

I. Macdougall, S. Thein, V. Abbate, 2010, Rapid communications in mass spectrometry : RCM.

Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy.

J. McMurray, P. Jhund, S. Anker, 2021, JACC. Heart failure.

Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial

J. McMurray, P. Jhund, S. Anker, 2021, Kidney360.

Iron Deficiency in CKD Without Concomitant Anemia

S. Anker, J. Butler, I. Macdougall, 2021, Kidney international reports.

Effects of Molidustat in the Treatment of Anemia in CKD.

I. Macdougall, T. Akizawa, J. Berns, 2018, Clinical journal of the American Society of Nephrology : CJASN.

New options for the anemia of chronic kidney disease

I. Macdougall, D. Goldsmith, D. Coyne, 2017, Kidney international supplements.

Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis

I. Macdougall, H. Choong, H. Park, 2017, Nephrology.

Anemia Management in the Elderly Dialysis Patient: Is It Different?

I. Macdougall, 2016 .

Peginesatide for anemia in chronic kidney disease.

I. Macdougall, S. Fishbane, A. Duliege, 2013, The New England journal of medicine.

Erythropoiesis-Stimulating Agent Therapy

I. Macdougall, 2013 .

Interventions for erythropoietin-resistant anaemia in dialysis patients.

David W. Johnson, E. Beller, V. Perkovic, 2013, The Cochrane database of systematic reviews.

Effect of red cell transfusions on future kidney transplantation.

I. Macdougall, G. Obrador, 2013, Clinical journal of the American Society of Nephrology : CJASN.

New anemia therapies: translating novel strategies from bench to bedside.

I. Macdougall, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Anaemia and chronic renal failure

I. Macdougall, 2011 .

Erythropoietic therapy: time for some changes

I. Macdougall, 2011 .

CHAPTER 79 – Anemia in Chronic Kidney Disease

I. Macdougall, K. Eckardt, 2010 .

Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up.

I. Macdougall, C. Tomson, D. Ansell, 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Prevalence and Management of Anaemia in Renal Transplant Recipients: Data from Ten European Centres

I. Macdougall, G. Choukroun, A. Courtney, 2010, Nephron Clinical Practice.

Anemia in PD Patients

A. Nissenson, I. Macdougall, A. Rastogi, 2009 .

Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients.

I. Macdougall, A. Dietrich, P. Bárány, 2009, Clinical nephrology.

Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD.

H. Burger, I. Macdougall, F. Locatelli, 2009, Journal of the American Society of Nephrology : JASN.

Development of Recombinant Erythropoietin and Erythropoietin Analogs

I. Macdougall, 2009 .

Anaemia ERBP Position statement.

I. Macdougall, 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Anemia in Patients with Chronic Kidney Disease not on Dialysis : Results of a Randomized Clinical Trial

F. C. Dougherty, I. Macdougall, F. Locatelli, 2008 .

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

F. C. Dougherty, I. Macdougall, F. Locatelli, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Epoetin-induced pure red cell aplasia: diagnosis and treatment

I. Macdougall, 2007, Current opinion in nephrology and hypertension.

Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe.

I. Macdougall, 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Restricting Red-Cell Transfusions in Cardiac Surgery: No Increase in AKI.

T. Richards, I. Macdougall, 2019, Journal of the American Society of Nephrology : JASN.

Predialysis Survey on Anemia Management: patient referral.

I. Macdougall, W. Hörl, F. Valderrábano, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Individualizing target haemoglobin concentrations--tailoring treatment for renal anaemia.

I. Macdougall, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.

Shreyas S Vasanawala, John Paul Finn, Xin Li, 2017, Kidney international.

A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.

I. Macdougall, W. Strauss, J. Hertel, 2014, Clinical journal of the American Society of Nephrology : CJASN.

High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis

J. McMurray, P. Jhund, S. Anker, 2021, Cardiovascular research.

Vascular access for hemodialysis in the elderly.

I. Macdougall, N. Mamode, R. Cacciola, 2011, Journal of vascular surgery.

Detection of functional iron deficiency during erythropoietin treatment: a new approach.

B. Bain, I. Cavill, I. Macdougall, 1992, BMJ.

European best practice guidelines 14-16: inadequate response to epoetin.

I. Macdougall, W. Hörl, F. Valderrábano, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Erythropoietin in anemia of renal failure in sickle cell disease.

I. Macdougall, S. Roger, A. Raine, 1991, The New England journal of medicine.

Iron Management in Chronic Kidney Disease : Report from a Kidney Disease : Improving Global Outcomes ( KDIGO ) Controversies Conference

D. Swinkels, C. Wanner, I. Macdougall, 2015 .

Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?

I. Macdougall, T. McDonagh, 2015, European journal of heart failure.

The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale

I. Macdougall, K. Bernard, W. Strauss, 2017, BMC Nephrology.

Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?

I. Macdougall, 2010, Current medical research and opinion.

Longitudinal Assessments of Erythropoietin-Stimulating Agent Responsiveness and the Association with Specific Clinical Outcomes in Dialysis Patients

C. Wanner, I. Macdougall, H. Scharnagl, 2014, Nephron Clinical Practice.

Ambulatory Blood Pressure Monitoring: An Invaluable Tool Comes of Age for Patients with Chronic Kidney Disease?

I. Macdougall, P. Sarafidis, Adam Rumjon, 2012, American Journal of Nephrology.

The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review

I. Macdougall, R. Moss‐Morris, J. Chilcot, 2016, Clinical kidney journal.

Correction to: The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale

I. Macdougall, K. Bernard, W. Strauss, 2018, BMC Nephrology.

I. Macdougall, J. Małyszko, M. Myśliwiec, 2013, Nephron Clinical Practice.

How to optimise anaemia therapy in peritoneal dialysis patients.

I. Macdougall, 2006, Contributions to nephrology.

Treatment Target in Polycythemia Vera

I. Macdougall, S. Fishbane, A. Duliege, 2013 .

Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres

I. Macdougall, R. Walker, A. Roche, 2009, Current medical research and opinion.

Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

J. McMurray, S. Anker, D. Wheeler, 2019, The New England journal of medicine.

Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data

J. McMurray, S. Anker, D. Wheeler, 2018, American Journal of Nephrology.

Randomized trial of intravenous iron-induced hypophosphatemia.

M. Wolf, I. Macdougall, G. Chertow, 2018, JCI insight.

Exercise Counselling Practices for Patients with Chronic Kidney Disease in the UK: A Renal Multidisciplinary Team Perspective

I. Macdougall, T. Mercer, R. Rush, 2014, Nephron Clinical Practice.

How to Improve Survival in Pre-Dialysis Patients

I. Macdougall, 2000, Nephron.

A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status

I. Macdougall, V. Allgar, S. Bhandari, 2021, BMC Nephrology.

Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease

I. Macdougall, P. Kalra, V. Allgar, 2020, American Journal of Nephrology.

A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease.

I. Macdougall, H. MacLaughlin, Sharlene A Cook, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Mortality and morbidity following exercise-based renal rehabilitation in patients with chronic kidney disease: the effect of programme completion and change in exercise capacity

I. Macdougall, E. Castle, S. Greenwood, 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

TITLE OF THE PROTOCOL: Clinical value and cost-effectiveness of intra-dialytic exercise for the improvement of health-related quality of life in people with stage 5 chronic kidney disease undergoing maintenance haemodialysis.

I. Macdougall, 2015 .

Intra-dialytic exercise training: a pragmatic approach.

I. Macdougall, T. Mercer, Victoria A Pursey, 2014, Journal of renal care.

Weight loss, adipokines, and quality of life after sleeve gastrectomy in obese patients with stages 3-4 CKD: a randomized controlled pilot study.

W. Hall, I. Macdougall, P. Chowdhury, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

European best practice guidelines 1-4: evaluating anaemia and initiating treatment.

I. Macdougall, W. Hörl, F. Valderrábano, 2000, Nephrology, Dialysis and Transplantation.

Cigarette smoking does not attenuate the cardiovascular effects of epoprostenol (prostacyclin) in humans.

I. Macdougall, J. O'grady, H. Pickles, 1982, British journal of clinical pharmacology.

The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin.

I. Macdougall, 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.

I. Macdougall, J. Kwan, R. Temple, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Normalizing hematocrit in renal failure: dangerous or desirable?

I. Macdougall, 2002 .

Should the Hematocrit Be Normalized in Dialysis and in Pre-ESRD Patients?

I. Macdougall, 2000, Blood Purification.

Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study

H. Burger, I. Macdougall, F. Locatelli, 2010, Current medical research and opinion.

Increased Platelet Volume in Patients with Adult Polycystic Kidney Disease

I. Macdougall, G. MacGregor, P. Bath, 1995 .

High cardiovascular event rates occur within the first weeks of starting hemodialysis

F. Kronenberg, S. Anker, D. Marcelli, 2015, Kidney international.

Effect of computer-assisted European Best Practice Guideline implementation on adherence and target attainment: ORAMA results.

I. Macdougall, F. Locatelli, A. Więcek, 2009, Journal of nephrology.

A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy

I. Macdougall, L. McMahon, M. Roberts, 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients

Ashutosh Kumar Singh, S. Solomon, J. McMurray, 2022, JAMA internal medicine.

Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)

April D. Miller, S. Xirasagar, I. Macdougall, 2012, Journal of General Internal Medicine.

Renal rehabilitation: the benefits, barriers and exercise options

I. Macdougall, T. Mercer, Ellen M O'Connor, 2014 .

Unusual presentation of aortic dissection with bilateral testicular pain and rapidly deteriorating renal function.

Dean Y. Huang, I. Macdougall, P. Donohoe, 2014, Urology.

Recent advances in erythropoietic agents in renal anemia.

I. Macdougall, 2006, Seminars in nephrology.

A randomized controlled study of iron supplementation in patients treated with erythropoietin.

I. Macdougall, B. Tucker, Jane Thompson, 1996, Kidney international.

Reassessments of ESAs for cancer treatment in the US and Europe.

J. Armitage, I. Macdougall, C. Bennett, 2010, Oncology.

How to get the best out of r-HuEPO.

I. Macdougall, 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Increased Expression of Erythropoiesis Inhibiting Cytokines (IFN-γ, TNF-α, IL-10, and IL-13) by T Cells in Patients Exhibiting a Poor Response to Erythropoietin Therapy

I. Macdougall, D. Kemeny, A. Mikhail, 2003 .

Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.

M. Cazzola, I. Macdougall, M. Pippard, 1997, Clinical nephrology.

Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent.

G. Mufti, I. Macdougall, N. Casadevall, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy.

I. Macdougall, D. Kemeny, A. Mikhail, 2003, Journal of the American Society of Nephrology : JASN.

CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.

I. Macdougall, 2005, Current hematology reports.

Guidelines on the Management of Renal Anemia

I. Macdougall, 2013 .

Erythropoiesis‐stimulating agent hyporesponsiveness (Review Article)

David W. Johnson, I. Macdougall, C. Pollock, 2007, Nephrology.

PRE-dialysis survey on anaemia management.

I. Macdougall, W. Hörl, F. Valderrábano, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Ace inhibitors and erythropoietin responsiveness.

I. Macdougall, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?

I. Macdougall, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Nomenclature in nephrology: preserving ‘renal’ and ‘nephro' in the glossary of kidney health and disease

Connie M. Rhee, S. Weisbord, S. Agarwal, 2021, Journal of Nephrology.

The use of erythropoietin in renal failure.

I. Macdougall, R. Hutton, G. Coles, 1991, Postgraduate medical journal.

Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial

I. Macdougall, P. Kalra, V. Allgar, 2022, Scientific Reports.

The available intravenous iron formulations: History, efficacy, and toxicology

I. Macdougall, M. Auerbach, 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

I. Macdougall, S. Bansal, L. McMahon, 2016, BMC Nephrology.

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients

I. Macdougall, P. Kalra, S. Bhandari, 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Safety of intravenous iron formulations: facts and folklore.

I. Macdougall, M. Auerbach, 2014, Blood transfusion = Trasfusione del sangue.

Use of intravenous iron supplementation in chronic kidney disease: an update.

I. Macdougall, P. Geisser, 2013, Iranian journal of kidney diseases.

OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease

I. Macdougall, W. Hörl, J. Rossert, 2007 .

Evolution of iv iron compounds over the last century.

I. Macdougall, 2009, Journal of renal care.

Rheological studies during treatment of renal anaemia with recombinant human erythropoietin

I. Macdougall, R. Hutton, G. Coles, 1991, British journal of haematology.

Measurement of hepcidin isoforms in human serum by liquid chromatography with high resolution mass spectrometry.

I. Macdougall, S. Handley, L. Couchman, 2017, Bioanalysis.

Intravenous iron supplementation in distance runners with low or suboptimal ferritin.

I. Macdougall, K. Thompson, P. Saunders, 2014, Medicine and science in sports and exercise.

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

P. Ponikowski, S. Anker, I. Macdougall, 2011, Nature Reviews Cardiology.

Hyporesponsiveness to Anemia Therapy—What are we Doing Wrong?

I. Macdougall, 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Role of uremic toxins in exacerbating anemia in renal failure.

I. Macdougall, Iain C. Macdougall, I. C. Macdougall, 2001, Kidney international. Supplement.

Poor response to erythropoietin: practical guidelines on investigation and management.

I. Macdougall, I. C. Macdougall, 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

I. Cavill, I. Macdougall, R. Hutton, 1990, British medical journal.

Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non‐diabetic chronic renal failure

D. Bosman, J. Marsden, I. Macdougall, 2002, Diabetic medicine : a journal of the British Diabetic Association.

Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency

P. Ponikowski, G. Filippatos, S. Anker, 2012, European journal of heart failure.

The iron revolution: Keeping abreast of the developments in iron therapy

T. Richards, I. Macdougall, G. Rodgers, 2021, American journal of hematology.

Treatment of anaemia in end-stage renal disease: A double-edged iron sword?

I. Macdougall, P. Kalra, R. Chinnadurai, 2019, EBioMedicine.

Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease

I. Macdougall, T. Akizawa, Hiroyasu Yamamoto, 2019, Nephron.

Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?

I. Macdougall, 2022, Current opinion in nephrology and hypertension.

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.

S. Solomon, J. McMurray, V. Jha, 2021, The New England journal of medicine.

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.

S. Solomon, J. McMurray, V. Jha, 2021, The New England journal of medicine.

Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production.

I. Macdougall, D. Kemeny, J. Ochola, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Intravenous Iron in Patients Undergoing Maintenance Hemodialysis

J. McMurray, S. Anker, D. Wheeler, 2019, The New England journal of medicine.

A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR)

J. Armitage, I. Macdougall, C. Bennett, 2012, Seminars in Thrombosis & Hemostasis.

Hemoglobin targets: the jury is still out.

I. Macdougall, F. Carrera, 2008, Clinical nephrology.

Impact of haemoglobin and erythropoietin dose changes on mortality : a secondary analysis of results from a randomized anaemia management trial

F. C. Dougherty, P. Kerr, I. Macdougall, 2022 .

Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients.

I. Macdougall, D. Cochlin, M. Davies, 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial

J. McMurray, P. Jhund, S. Anker, 2022, Kidney international reports.

Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.

J. McMurray, S. Anker, D. Wheeler, 2020, Journal of the American Society of Nephrology : JASN.

Intravenous iron: a framework for changing the management of iron deficiency.

I. Macdougall, A. Gafter-Gvili, M. Auerbach, 2020, The Lancet. Haematology.

Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk

W. Winkelmayer, I. Macdougall, T. Ganz, 2020, Kidney medicine.

Intravenous Iron Use in the Care of Patients with Kidney Disease.

I. Macdougall, I. C. Macdougall, 2019, Clinical journal of the American Society of Nephrology : CJASN.

Monitoring of iron status and iron supplementation in patients treated with erythropoietin.

I. Macdougall, Iain C. Macdougall, 1994, Current opinion in nephrology and hypertension.

A response by Strauss et al. to “a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia”

I. Macdougall, G. Chertow, W. Strauss, 2018, American journal of hematology.

Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?

I. Macdougall, N. Casadevall, J. Rossert, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study

I. Macdougall, N. Casadevall, K. Eckardt, 2004, The Lancet.

Intravenous iron: out of sight, out of mind.

I. Macdougall, M. Muñoz, M. Auerbach, 2018, The Lancet. Haematology.

Iron management in chronic kidney disease: Global Outcomes” (KDIGO) Controversies Conference

D. Swinkels, C. Wanner, I. Macdougall, 2015 .

The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin.

I. Cavill, I. Macdougall, N. Lewis, 1990, Nephrology, Dialysis and Transplantation.

The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial

D. Wheeler, I. Macdougall, S. Ayis, 2022, BMC Nephrology.

I. Macdougall, V. Allgar, S. Bhandari, 2020, BMC Nephrology.

The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial

M. Taal, D. Wheeler, I. Macdougall, 2020, Clinical Kidney Journal.

Intravenous iron in patients undergoing maintenance hemodialysis

J. McMurray, S. Anker, I. Macdougall, 2019 .

Intravenous iron Intravenous Iron in Patients Undergoing Maintenance Hemodialysis

J. McMurray, S. Anker, D. Wheeler, 2019 .

Obesity Does Not Influence Hepcidin and Hemojuvelin Levels in Hemodialysis Patients

I. Macdougall, S. Bansal, P. Sarafidis, 2013, Nephron Clinical Practice.

Intravenous iron dosing and infection risk in hemodialysis patients: a pre-specified secondary analysis of the PIVOTAL trial

J. McMurray, S. Anker, D. Wheeler, 2020 .

Evaluation of a pragmatic exercise rehabilitation programme in chronic kidney disease.

I. Macdougall, T. Mercer, R. Rush, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients.

I. Macdougall, P. Sidhu, G. Muir, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

How important is transfusion avoidance in 2013?

I. Macdougall, G. Obrador, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The inflammatory response and epoetin sensitivity.

I. Macdougall, A. Cooper, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Iron in Patients with Non-Dialysis Dependent An analysis of the FIND-CKD Trial.

I. Macdougall, K. Eckardt, Maureen Cronin, 2016 .

What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency.

I. Macdougall, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics

I. Macdougall, D. Kular, 2018, Pediatric Nephrology.

Rationale and design of a randomised trial of intravenous iron in patients with heart failure

I. Macdougall, M. Petrie, J. Cleland, 2022, Heart.

Hemojuvelin and iron metabolism in kidney and heart allograft recipients.

I. Macdougall, J. Małyszko, P. Przybyłowski, 2013, Transplantation proceedings.

Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions

I. Macdougall, 2017, Clinical kidney journal.

Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha.

I. Macdougall, M. Yaqoob, C. Breen, 1999, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions

I. Macdougall, K. Bernard, W. Strauss, 2017, Journal of blood medicine.

Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure.

I. Macdougall, D. Kemeny, A. Mikhail, 2004, Journal of the American Society of Nephrology : JASN.

The Normal Haematocrit Trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin?

I. Macdougall, E. Ritz, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).

I. Macdougall, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Iron deficiency in chronic heart failure: case‐based practical guidance

I. Macdougall, D. Spahn, M. Cappellini, 2018, ESC heart failure.

Peginesatide in patients with anemia undergoing hemodialysis.

I. Macdougall, F. Locatelli, A. Więcek, 2013, The New England journal of medicine.

CREATE: new strategies for early anaemia management in renal insufficiency.

I. Macdougall, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome

I. Macdougall, R. Hangartner, E. E. Bowen, 2016, Journal of general internal medicine.

Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.

I. Macdougall, M. Ashenden, 2009, Advances in chronic kidney disease.

Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward

I. Macdougall, F. Locatelli, A. Więcek, 2004 .

HYPERMINERALOCORTICOIDISM DUE TO ADRENAL CARCINOMA: PLASMA CORTICOSTEROIDS and THEIR RESPONSE TO ACTH and ANGIOTENSIN II

I. Macdougall, C. Isles, A. Lever, 1987, Clinical endocrinology.

Novel erythropoiesis-stimulating agents: a new era in anemia management.

I. Macdougall, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Benjamin R. Szwejkowski, J. McMurray, I. Matthews, 2022, The Lancet.

Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.

F. C. Dougherty, B. Reigner, I. Macdougall, 2006, Clinical journal of the American Society of Nephrology : CJASN.

Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management

N. Kassebaum, I. Macdougall, G. Rogler, 2017, American journal of hematology.

Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.

I. Macdougall, J. Matcham, S. Gray, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Intravenous administration of iron in epoetin-treated haemodialysis patients--which drugs, which regimen?

I. Macdougall, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial

I. Macdougall, K. Bernard, W. Strauss, 2019, Clinical nephrology.

Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit.

I. Macdougall, J. Harchowal, G. Chandler, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Serum C-reactive protein as a marker for infection and inflammation in regular dialysis patients.

I. Macdougall, I. Harper, C. McIntyre, 1997, Clinical nephrology.

Erythropoietin treatment in the neuropsychiatric porphyrias.

A. Winkler, J. Marsden, I. Macdougall, 2003, Clinica chimica acta; international journal of clinical chemistry.

Recombinant erythropoietin in clinical practice

I. Macdougall, T. Littlewood, G. Marx, 2003, Postgraduate medical journal.

MO067LONG-TERM PULSE WAVE VELOCITY AND VO2PEAK OUTCOMES WITH 12 WEEKS OF AEROBIC OR RESISTANCE TRAINING IN KIDNEY TRANSPLANT RECIPIENTS: A FOLLOW-UP OF THE EXERT STUDY

I. Macdougall, D. Goldsmith, Ellen M O'Connor, 2016 .

SP309SAFETY AND EFFICACY OF MOLIDUSTAT IN ERYTHROPOIESIS STIMULATING AGENTS (ESA) PRE-TREATED ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (CKD-ND)

I. Macdougall, T. Akizawa, Thilo Krüger, 2016 .

SO036MOLIDUSTAT INCREASES HAEMOGLOBIN IN ERYTHROPOIESIS STIMULATING AGENTS (ESA)-NAIVE ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (CKD-ND)

I. Macdougall, T. Akizawa, J. Berns, 2016 .

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial

G. Filippatos, M. Metra, J. Butler, 2022, European journal of heart failure.

Iron Treatment Strategies in Nondialysis CKD.

I. Macdougall, 2016, Seminars in nephrology.

The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia

I. Macdougall, P. Kalra, S. Bhandari, 2021, Kidney international reports.

Intravenous iron sucrose: establishing a safe dose.

I. Macdougall, J. Harchowal, G. Chandler, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

How to diagnose and correct iron deficiency during r-huEPO therapy--a consensus report.

I. Cavill, I. Macdougall, W. Hörl, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

European best practice guidelines 6-8: assessing and optimizing iron stores.

I. Macdougall, W. Hörl, F. Valderrábano, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Experience With Intravenous Iron in Nephrology

I. Macdougall, 2006 .

Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?

I. Macdougall, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Experience with a new method for percutaneous renal biopsy.

D. Wheeler, I. Macdougall, K. Donovan, 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Posttransplantation Anemia in Adult Renal Allograft Recipients: Prevalence and Predictors

I. Macdougall, D. Goldsmith, A. Covic, 2006, Transplantation.

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients A Randomized Clinical Trial

Ashutosh Kumar Singh, J. McMurray, V. Jha, 2022 .

The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.

F. C. Dougherty, I. Macdougall, D. Ellison, 2007, Clinical nephrology.

The ASCEND-ND trial: study design and participant characteristics

Ashutosh Kumar Singh, J. McMurray, V. Jha, 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The Role of Iron in Calciphylaxis—A Current Review

I. Macdougall, I. Ford, P. Kalra, 2022, Journal of clinical medicine.

European best practice guidelines 17-18: adverse effects.

I. Macdougall, W. Hörl, F. Valderrábano, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

European best practice guidelines 9-13: anaemia management.

I. Macdougall, W. Hörl, F. Valderrábano, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

European Survey on Anaemia Management (ESAM) - Patients and methods

I. Macdougall, K. Milisen, W. Hörl, 2000 .

Iron therapy for managing anaemia in chronic kidney disease.

I. Macdougall, 2018, Current opinion in nephrology and hypertension.

Oral Iron Therapy: After Three Centuries, It Is Time for a Change.

I. Macdougall, M. Auerbach, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

New data on the safety of IV iron-but why the discrepancy with FIND-CKD?

I. Macdougall, S. Roger, 2015, Kidney international.

Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial

I. Macdougall, K. Eckardt, F. Carrera, 2017, Clinical nephrology.

Desmopressin use prior to renal transplant biopsy—does it fit?

I. Macdougall, Sapna Shah, S. Jayawardene, 2014, Clinical kidney journal.

Correction of Epoetin-Resistant Megaloblastic Anaemia following Vitamin B12 and Folate Administration

I. Macdougall, C. Breen, 1999, Nephron.

Metabolic Adjuvants to Erythropoietin Therapy

I. Macdougall, 1999, Mineral and Electrolyte Metabolism.

Poor response to erythropoietin

I. Macdougall, 1995, BMJ.

On the safety of intravenous iron, evidence trumps conjecture

J. Adamson, I. Macdougall, F. Locatelli, 2015, Haematologica.

Darbepoetin alfa: a new therapeutic agent for renal anemia.

I. Macdougall, 2002, Kidney international. Supplement.

Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously.

I. Cavill, I. Macdougall, R. Hutton, 1989, BMJ.

Massive haemoperitoneum due to rupture of splenic infarct during CAPD.

I. Macdougall, J. Turney, N. S. Kanagasundaram, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Subcutaneous recombinant erythropoietin in the treatment of renal anaemia in CAPD patients.

I. Cavill, I. Macdougall, M. Davies, 1990 .

Iron deficiency anaemia

I. Macdougall, L. Peyrin-Biroulet, P. Cacoub, 2016, The Lancet.

Step-Wise Management of Anemia in Patients With Chronic Kidney Disease in Primary Care: Qualitative Study

S. de Lusignan, I. Macdougall, T. Chan, 2023, Journal of primary care & community health.

Anaemia Management in Chronic Kidney Disease

I. Macdougall, 2014 .

TREATMENT OF ULCERATIVE COLITIS WITH RECTAL STEROIDS

I. Macdougall, 1963 .

Prophylactic Ureteric Stents in Renal Transplant Recipients: A Multicenter Randomized Controlled Trial of Early Versus Late Removal

I. Macdougall, I. Rebollo-Mesa, S. Marks, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Regulatory and clinical considerations for biosimilar oncology drugs.

J. Armitage, I. Macdougall, C. Bennett, 2014, The Lancet. Oncology.

IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors

I. Macdougall, J. Lozano, T. Tree, 2017, Proceedings of the National Academy of Sciences.

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol

M. Landray, J. Emberson, C. Baigent, 2013, Transplantation research.

Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)

Antonio Santoro, Francesco Locatelli, A. Santoro, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Notice

J. Adamson, J. McMurray, I. Macdougall, 2012, Kidney International Supplements.

KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease

J. Adamson, I. Macdougall, P. Parfrey, 2012 .

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency

P. Ponikowski, A. Cohen-Solal, M. Metra, 2017, Circulation.

Iron status in patients with chronic heart failure.

P. Ponikowski, J. McMurray, M. Gheorghiade, 2013, European heart journal.

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.

I. Macdougall, N. Casadevall, W. Hörl, 2012, Kidney international.

Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives

P. Ponikowski, S. Anker, I. Macdougall, 2012, European heart journal.

Does Intragastric Balloon Treatment for Obesity in Chronic Kidney Disease Heighten Acute Kidney Injury Risk?

W. Hall, I. Macdougall, J. Oben, 2016, American Journal of Nephrology.

Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines.

I. Macdougall, A. Cooper, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients

I. Macdougall, F. Locatelli, S. Fishbane, 2017, American Journal of Nephrology.

Case of Oesophageal Carcinoma

I. Macdougall, 1949, British medical journal.

Poor response to erythropoietin: Authors' reply

I. Cavill, I. Macdougall, R. Hutton, 1989 .

Technetium-99m methoxy isobutyl isonitrile (MIBI) imaging of the parathyroid glands in patients with renal failure.

I. Macdougall, K. Britton, L. Baker, 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

F. C. Dougherty, P. Kerr, I. Macdougall, 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Prostate-specific antigen levels in patients receiving long-term dialysis.

I. Macdougall, C. McIntyre, L. Harper, 1995, British journal of urology.

Serum Hemojuvelin and Hepcidin Levels in Chronic Kidney Disease

I. Macdougall, S. Bansal, P. Sarafidis, 2012, American Journal of Nephrology.

Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin.

I. Macdougall, P. Sarafidis, H. MacLaughlin, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Novel erythropoiesis stimulating protein.

I. Macdougall, I C Macdougall, 2000, Seminars in nephrology.

Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

I. Macdougall, J. Egrie, B. Jenkins, 1999, Journal of the American Society of Nephrology : JASN.

Optimizing erythropoietin therapy.

I. Macdougall, 1999, Current opinion in hematology.

Guideline for the laboratory diagnosis of functional iron deficiency

I. Cavill, I. Macdougall, T. Littlewood, 2013, British journal of haematology.

Pure red cell aplasia induced by erythropoiesis-stimulating agents.

I. Macdougall, N. Casadevall, W. Hörl, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Over 5 years of darbepoetin alfa: two case histories

I. Macdougall, A. Roche, 2004, Expert opinion on pharmacotherapy.

Serum erythropoietin levels may be inappropriately low in the acute neuropsychiatric porphyrias.

A. Winkler, J. Marsden, I. Macdougall, 2002, Clinica chimica acta; international journal of clinical chemistry.

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

I. Macdougall, N. Casadevall, K. Eckardt, 2009, The New England journal of medicine.

Iron and the anaemia of chronic disease: a review and strategic recommendations

I. Cavill, I. Macdougall, G. Bailie, 2006, Current medical research and opinion.

Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe?

I. Macdougall, F. Locatelli, K. Eckardt, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Peginesatide for the treatment of anemia due to chronic kidney disease – an unfulfilled promise

I. Macdougall, C. Bennett, Charles L Bennett, 2016, Expert opinion on drug safety.

Risk for chronic kidney disease increases with obesity: Health Survey for England 2010

W. Hall, I. Macdougall, T. Sanders, 2015, Public Health Nutrition.

Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies

I. Macdougall, T. Akizawa, K. Iekushi, 2019, American Journal of Nephrology.

Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the “ANTICIPATE” Framework

I. Macdougall, C. Bennett, Y. T. Yang, 2018, American journal of therapeutics.

Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.

I. Macdougall, A. Więcek, P. Schatz, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Preoperative intravenous iron for anaemia in elective major open abdominal surgery: the PREVENTT RCT.

J. Browne, T. Richards, I. Macdougall, 2021, Health technology assessment.

Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial

I. Macdougall, K. Eckardt, Maureen Cronin, 2016, PloS one.

What is the Future of Renal Anemia Management

I. Macdougall, 2013 .

What is the Cause of Renal Anemia

I. Macdougall, 2013 .

Iron supplementation in nephrology and oncology: what do we have in common?

I. Macdougall, 2011, The oncologist.

Neutrophil Gelatinase-Associated Lipocalin and Hepcidin: What Do They Have in Common and Is There a Potential Interaction?

I. Macdougall, V. Tesar, J. Małyszko, 2010, Kidney and Blood Pressure Research.

Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia

I. Macdougall, K. Eckardt, 2006, The Lancet.

Current status of the measurement of blood hepcidin levels in chronic kidney disease.

I. Macdougall, R. Hider, S. Bansal, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia.

I. Macdougall, 2008, Current opinion in investigational drugs.

Quality of life and anemia: the nephrology experience.

I. Macdougall, 1998, Seminars in oncology.

Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure

P. Ponikowski, S. Anker, I. Macdougall, 2015, Croatian medical journal.

Participation in a Structured Weight Loss Program and All-Cause Mortality and Cardiovascular Morbidity in Obese Patients With Chronic Kidney Disease.

W. Hall, I. Macdougall, T. Sanders, 2015, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease.

W. Hall, I. Macdougall, K. Campbell, 2012, American journal of hypertension.

Laparoscopic Sleeve Gastrectomy is a Novel and Effective Treatment for Obesity in Patients with Chronic Kidney Disease

W. Hall, I. Macdougall, H. MacLaughlin, 2011, Obesity Surgery.

Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.

I. Macdougall, H. MacLaughlin, Sharlene A Cook, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

An Epidemiological Study of Hemodialysis Patients Based on the European Fresenius Medical Care Hemodialysis Network: Results of the ARO Study

Florian Kronenberg, David C. Wheeler, Jürgen Floege, 2010, Nephron Clinical Practice.

Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity

I. Macdougall, N. Casadevall, O. Hainzl, 2011, Pharmaceutical Research.

Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another

I. Macdougall, 2004, Current medical research and opinion.

A “Set Point” for Water Homeostasis Disturbed with Altered Kidney Transplantation Outcome

I. Macdougall, T. Richards, 2019 .

Biosimilar epoetins. Author's reply

I. Macdougall, A. Covic, 2009 .

Biosimilar epoetins.

I. Macdougall, 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

European best practice guidelines 5: target haemoglobin.

I. Macdougall, W. Hörl, F. Valderrábano, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A prospective study of fatigue trajectories among in‐centre haemodialysis patients

I. Macdougall, S. Norton, R. Moss‐Morris, 2019, British journal of health psychology.

‘It's when you're not doing too much you feel tired’: A qualitative exploration of fatigue in end‐stage kidney disease

I. Macdougall, R. Moss‐Morris, J. Chilcot, 2017, British journal of health psychology.

Correction to: Psychosocial and Clinical Correlates of Fatigue in Haemodialysis Patients: the Importance of Patients’ Illness Cognitions and Behaviours

I. Macdougall, R. Moss‐Morris, J. Chilcot, 2017, International Journal of Behavioral Medicine.

Psychosocial and Clinical Correlates of Fatigue in Haemodialysis Patients: the Importance of Patients’ Illness Cognitions and Behaviours

I. Macdougall, R. Moss‐Morris, J. Chilcot, 2016, International Journal of Behavioral Medicine.

Measuring fatigue in haemodialysis patients: The factor structure of the Chalder Fatigue Questionnaire (CFQ).

I. Macdougall, R. Moss‐Morris, J. Chilcot, 2016, Journal of psychosomatic research.

Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?

I. Macdougall, F. Locatelli, A. Więcek, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

Mark E. Thomas, A. Santoro, G. Remuzzi, 2017, BMC Nephrology.

The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale

I. Macdougall, K. Eckardt, F. Carrera, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study

P. Ponikowski, K. Dickstein, G. Filippatos, 2015, European journal of heart failure.

Feasibility of randomized controlled trials and long-term implementation of interventions: Insights from a qualitative process evaluation of the PEDAL trial

I. Macdougall, T. Mercer, C. Bulley, 2023, Frontiers in Rehabilitation Sciences.

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Benjamin R. Szwejkowski, J. McMurray, I. Matthews, 2022, The Lancet.

Optimal Iron Management in Patients Receiving Erythropoietin Therapy

I. Macdougall, 1998 .

Subcutaneous erythropoietin therapy: comparison of three different sites of injection.

I. Macdougall, G. Coles, J. Miles, 1991, Contributions to nephrology.

Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment.

I. Macdougall, G. Coles, D. Roberts, 1989, Contributions to nephrology.

Complement Activation-Related Pseudo-Allergy: A Fresh Look at Hypersensitivity Reactions to Intravenous Iron

I. Macdougall, K. Vernon, 2016, American Journal of Nephrology.

Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial

J. Browne, S. Anker, D. Brealey, 2020, The Lancet.

Factors precipitating erythropoiesis‐stimulating agent responsiveness in a European haemodialysis cohort: case‐crossover study†

D. Marcelli, I. Macdougall, K. Eckardt, 2015, Pharmacoepidemiology and drug safety.

Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial

S. Solomon, J. McMurray, V. Jha, 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

I. Macdougall, D. Spahn, C. Breymann, 2020, Advances in Therapy.

What is Renal Anemia

I. Macdougall, 2013 .

Obesity and recovery from acute kidney injury (Ob AKI): a prospective cohort feasibility study

I. Macdougall, N. Selby, C. McIntyre, 2019, BMJ Open.

Iron deficiency anaemia

I. Macdougall, L. Peyrin-Biroulet, P. Cacoub, 2007 .

Fatigue in Prevalent Haemodialysis Patients Predicts All-cause Mortality and Kidney Transplantation.

I. Macdougall, S. Norton, R. Moss‐Morris, 2018, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice

G. Rosano, T. Richards, I. Macdougall, 2021, Annals of medicine.

Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial

S. Solomon, J. McMurray, V. Jha, 2021, Nephrology, Dialysis and Transplantation.

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

I. Macdougall, K. Eckardt, F. Carrera, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.

H. Uno, S. Solomon, M. Pfeffer, 2011, Clinical journal of the American Society of Nephrology : CJASN.

ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.

F Locatelli, I. Macdougall, F. Locatelli, 2008, Journal of nephrology.

Renal Anemia: Comparing Current Eastern and Western European Management Practice (ORAMA)

I. Macdougall, F. Locatelli, A. Więcek, 2008, Renal failure.

An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic

I. Macdougall, A. Hutchings, Aruna Jeans, 2013, Journal of medical economics.

OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD)

C. Wanner, I. Macdougall, L. Gesualdo, 2007 .

Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.

I. Macdougall, A. Roche, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes

J. McMurray, S. Anker, D. Wheeler, 2023, Journal of nephrology.

Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?

B. Bacon, I. Macdougall, J. Núñez, 2018, American Journal of Nephrology.

Management of anaemia in renal failure.

I. Macdougall, 1999, EDTNA/ERCA journal.

Randomized Trial—PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis

M. Taal, D. Wheeler, I. Macdougall, 2021, Kidney international reports.

Present and future strategies in the treatment of renal anaemia.

I. Macdougall, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Aerobic or Resistance Training and Pulse Wave Velocity in Kidney Transplant Recipients: A 12-Week Pilot Randomized Controlled Trial (the Exercise in Renal Transplant [ExeRT] Trial).

I. Macdougall, T. Mercer, D. Goldsmith, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Iron management in patients on rHuEpo

I. Cavill, I. Macdougall, C. Winearls, 1997 .

Special issue: iron therapy in patients with chronic kidney disease

I. Macdougall, 2017, Clinical Kidney Journal.

Stepwise Approach to Anemia Management in Patients with Chronic Kidney Disease

I. Macdougall, 2013 .

Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.

I. Macdougall, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Cognitive-behavioural therapy (CBT) for renal fatigue (BReF): a feasibility randomised-controlled trial of CBT for the management of fatigue in haemodialysis (HD) patients

I. Macdougall, K. Farrington, S. Norton, 2018, BMJ Open.

Practical guidelines for the use of NESP in treating renal anaemia.

I. Macdougall, F. Locatelli, R. Krediet, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options.

I. Macdougall, N. Casadevall, J. Rossert, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Erythropoietin and renal failure.

I. Macdougall, 2003, Current hematology reports.

Intravenous iron therapy in non-dialysis CKD patients.

I. Macdougall, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Once-weekly erythropoietic therapy: is there a difference between the available preparations?

I. Macdougall, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Improvement of erythropoietin-resistant anaemia after renal transplantation in patients with homozygous sickle-cell disease.

I. Macdougall, C. Breen, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The association between iron deficiency and outcomes: a secondary analysis of the intravenous iron therapy to treat iron deficiency anaemia in patients undergoing major abdominal surgery (PREVENTT) trial

Sharon K Martin, A. Crook, S. Anker, 2022, Anaesthesia.

Interstitial nephritis and primary biliary cirrhosis: a new association?

R. N. Macsween, I. Macdougall, J. Whitworth, 1987, Clinical nephrology.

Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial.

B. Hendry, I. Macdougall, T. Mercer, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Hypoglycaemia in acute myelomonoblastic leukaemia.

I. Macdougall, B. Frier, 1985, British medical journal.

Behavioural change and exercise therapy for patients with CKD

I. Macdougall, Ellen M O'Connor, S. Greenwood, 2017 .

Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT.

M. Taal, D. Wheeler, I. Macdougall, 2021, Health technology assessment.

Successful treatment of acute D-lactate encephalopathy by haemodialysis.

I. Macdougall, R. Walker, C. Tomson, 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Improvement in anaemia following renal transplantation but not after erythropoietin therapy in a patient with sickle-cell disease.

I. Cavill, I. Macdougall, A. Stephens, 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Long-term pulse wave velocity outcomes with aerobic and resistance training in kidney transplant recipients – A pilot randomised controlled trial

I. Macdougall, T. Mercer, D. Goldsmith, 2017, PloS one.

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial

I. Macdougall, 2007, Trials.

Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin.

I. Macdougall, I. C. Macdougall, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The ASCEND-NHQ trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis-dependent chronic kidney disease.

Ashutosh Kumar Singh, V. Jha, D. Wheeler, 2023, Kidney international.

Supplemental iron via dialysate: a novel mode of delivery for hemodialysis patients.

I. Macdougall, 2015, Kidney international.

Feasibility trial of cognitive behavioural therapy for fatigue in haemodialysis (BReF intervention).

I. Macdougall, K. Farrington, S. Norton, 2020, Journal of pain and symptom management.

C.E.R.A., a once-monthly ESA: is it living up to expectations?

I. Macdougall, 2009 .

Exercise Therapy in Individuals With Chronic Kidney Disease: A Systematic Review and Synthesis of the Research Evidence

I. Macdougall, T. Mercer, S. Greenwood, 2013, Annual Review of Nursing Research.

Exercise Therapy in Individuals With Chronic Kidney Disease: A Systematic Review and Synthesis of the Research Evidence

I. Macdougall, T. Mercer, S. Greenwood, 2013, Annual Review of Nursing Research.

Iron Metabolism, Hepcidin and Anemia in Orthotopic Heart Transplantation Treated with mTOR: 1391

I. Macdougall, J. Małyszko, P. Przybyłowski, 2012 .

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial

G. Remuzzi, C. Wanner, M. Jadoul, 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Dental Attendance and Self-reported Oral Health Status of Renal Dialysis Patients: A Comparison of Results with the UK Adult Dental Health Survey.

I. Macdougall, Parmjit Singh, S. Warnakulasuriya, 2016, Oral health & preventive dentistry.

A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient non-anemic patients with chronic kidney disease

D. Wheeler, I. Macdougall, S. Ayis, 2023, Kidney International Reports.

MP416EFFICACY OF ORAL IRON FOR TREATING IRON DEFICIENCY IN ANAEMIC PATIENTS WITH NON-DIALYSIS DEPENDENT CKD (ND-CKD)

I. Macdougall, K. Eckardt, F. Carrera, 2017 .

A model to predict haematopoietic non-response to oral iron in patients with non-dialysis dependent ckd (ND-CKD): an analysis from the find-ckd trial

I. Macdougall, K. Eckardt, F. Carrera, 2016 .

THE SAFETY OF INTRAVENOUS (IV) FERRIC CARBOXYMALTOSE (FCM) IN PATIENTS WITH NON-DIALYSIS DEPENDENT CKD (ND-CKD) : 1-YEAR RESULTS FROM THE FIND-CKD TRIAL

I. Macdougall, K. Eckardt, F. Carrera, 2016 .

FO016HEPCIDIN RESPONSE TO IRON THERAPY IN PATIENTS WITH NON-DIALYSIS CKD: AN ANALYSIS OF THE FIND-CKD TRIAL

I. Macdougall, K. Eckardt, S. Bansal, 2015 .

Possible Relationship between Neutrophil Gelatinase-Associated Lipocalin, Hepcidin, and Inflammation in Haemodialysed Patients

I. Macdougall, J. Małyszko, P. Koźmiński, 2010, Nephron Clinical Practice.

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)

Ashutosh Kumar Singh, V. Jha, I. Macdougall, 2023, American Journal of Nephrology.

Acute intermittent porphyria and chronic renal failure.

J. Marsden, I. Macdougall, T. Peters, 2008, Clinical nephrology.

Reply — Orlistat and renal failure

I. Macdougall, H. MacLaughlin, 2007 .

Hypoglycaemic coma associated with gastric carcinoma.

I. Macdougall, B. Frier, S. Fleming, 1986, Postgraduate medical journal.

The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial

M. Taal, D. Wheeler, I. Macdougall, 2020, Clinical kidney journal.

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol

M. Landray, J. Emberson, C. Baigent, 2013, Transplantation research.

IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors

I. Macdougall, J. Lozano, T. Tree, 2017, Proceedings of the National Academy of Sciences of the United States of America.

Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.

I. Macdougall, S. Fishbane, P. Pergola, 2013, The New England journal of medicine.

Peginesatide in patients with anemia undergoing hemodialysis.

I. Macdougall, F. Locatelli, A. Więcek, 2013, The New England journal of medicine.

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

I. Macdougall, N. Casadevall, K. Eckardt, 2009, The New England journal of medicine.

Iron deficiency anaemia

I. Macdougall, L. Peyrin-Biroulet, P. Cacoub, 2016, The Lancet.

Keynote Lecture How to get the best out of r-HuEPO

I. Macdougall, I. C. Macdougall, 1995 .

Randomized trial of intravenous iron-induced hypophosphatemia.

I. Macdougall, G. Chertow, W. Strauss, 2018, JCI insight.

Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.

I. Macdougall, M. Ashenden, 2009, Advances in chronic kidney disease.

Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality.

O. Djurdjev, I. Macdougall, R. Walker, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease.

W. Hall, I. Macdougall, K. Campbell, 2012, American journal of hypertension.

Mortality and morbidity following exercise-based renal rehabilitation in patients with chronic kidney disease: the effect of programme completion and change in exercise capacity

I. Macdougall, E. Castle, S. Greenwood, 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis

G. Filippatos, M. Metra, J. Butler, 2023, Circulation.

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

I. Macdougall, E. Daugas, K. Eckardt, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Iron supplementation in nephrology and oncology: what do we have in common?

I. Macdougall, 2011, The oncologist.

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

G. Filippatos, M. Metra, F. Ruschitzka, 2023, Cardiovascular Diabetology.

How important is transfusion avoidance in 2013?

I. Macdougall, G. Obrador, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome

I. Macdougall, R. Hangartner, E. E. Bowen, 2016, Journal of General Internal Medicine.

Complement Activation-Related Pseudo-Allergy: A Fresh Look at Hypersensitivity Reactions to Intravenous Iron

I. Macdougall, K. Vernon, 2016, American Journal of Nephrology.